A single mutation in the E2 glycoprotein of hepatitis C virus broadens the claudin specificity for its infection

被引:0
|
作者
Yoshitaka Shirasago
Hidesuke Fukazawa
Shotaro Nagase
Yoshimi Shimizu
Tomoharu Mizukami
Takaji Wakita
Tetsuro Suzuki
Hideki Tani
Masuo Kondoh
Takuya Kuroda
Satoshi Yasuda
Yoji Sato
Kentaro Hanada
Masayoshi Fukasawa
机构
[1] National Institute of Infectious Diseases,Department of Biochemistry and Cell Biology
[2] National Institute of Infectious Diseases,Department of Quality Assurance, Radiation Safety, and Information System
[3] Osaka University,Graduate School of Pharmaceutical Sciences
[4] Teikyo Heisei University,Department of Pharmaceutical Sciences
[5] National Institute of Infectious Diseases,Department of Infectious Diseases
[6] Hamamatsu University School of Medicine,Department of Virology
[7] Toyama Institute of Health,Division of Cell
[8] National Institute of Health Sciences,Based Therapeutic Products
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Entry of the hepatitis C virus (HCV) into host cells is a multistep process mediated by several host factors, including a tight junction protein claudin-1 (CLDN1). We repeatedly passaged HCV-JFH1-tau, an HCV substrain with higher infectivity, on Huh7.5.1-8 cells. A multi-passaged HCV-JFH1-tau lot was infectious to CLDN1-defective S7-A cells, non-permissive to original HCV-JFH1-tau infection. We identified a single mutation, M706L, in the E2 glycoprotein of the HCV-JFH1-tau lot as an essential mutation for infectivity to S7-A cells. The pseudovirus JFH1/M706L mutant could not infect human embryonic kidney 293 T (HEK293T) cells lacking CLDN family but infected HEK293T cells expressing CLDN1, CLDN6, or CLDN9. Thus, this mutant virus could utilize CLDN1, and other CLDN6 and CLDN9, making HCV possible to infect cells other than hepatocytes. iPS cells, one of the stem cells, do not express CLDN1 but express CLDN6 and other host factors required for HCV infection. We confirmed that the HCV-JFH1-tau-derived mutant with an M706L mutation infected iPS cells in a CLDN6-dependent manner. These results demonstrated that a missense mutation in E2 could broaden the CLDN member specificity for HCV infection. HCV may change its receptor requirement through a single amino acid mutation and infect non-hepatic cells.
引用
收藏
相关论文
共 50 条
  • [1] A single mutation in the E2 glycoprotein of hepatitis C virus broadens the claudin specificity for its infection
    Shirasago, Yoshitaka
    Fukazawa, Hidesuke
    Nagase, Shotaro
    Shimizu, Yoshimi
    Mizukami, Tomoharu
    Wakita, Takaji
    Suzuki, Tetsuro
    Tani, Hideki
    Kondoh, Masuo
    Kuroda, Takuya
    Yasuda, Satoshi
    Sato, Yoji
    Hanada, Kentaro
    Fukasawa, Masayoshi
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [2] A model for the hepatitis C virus envelope glycoprotein E2
    Yagnik, AT
    Lahm, A
    Meola, A
    Roccasecca, RM
    Ercole, BB
    Nicosia, A
    Tramontano, A
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2000, 40 (03) : 355 - 366
  • [3] Hepatitis C Virus E2 Envelope Glycoprotein Core Structure
    Kong, Leopold
    Giang, Erick
    Nieusma, Travis
    Kadam, Rameshwar U.
    Cogburn, Kristin E.
    Hua, Yuanzi
    Dai, Xiaoping
    Stanfield, Robyn L.
    Burton, Dennis R.
    Ward, Andrew B.
    Wilson, Ian A.
    Law, Mansun
    SCIENCE, 2013, 342 (6162) : 1090 - 1094
  • [4] The Neutralizing Face of Hepatitis C virus E2 envelope Glycoprotein
    Tzarum, Netanel
    Wilson, Ian A.
    Law, Mansun
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [5] In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection
    Mailly, Laurent
    Wrensch, Florian
    Heydmann, Laura
    Fauvelle, Catherine
    Brignon, Nicolas
    Zeisel, Mirjam B.
    Pessaux, Patrick
    Keck, Zhen-yong
    Schuster, Catherine
    Fuerst, Thomas R.
    Foung, Steven K. H.
    Baumert, Thomas F.
    ANTIVIRAL RESEARCH, 2019, 162 : 136 - 141
  • [6] Immunologic events during the incubation period of hepatitis C virus infection: the role of antibodies to E2 glycoprotein
    Psichogiou, M
    Katsoulidou, A
    Vaindirli, E
    Francis, B
    Lee, SR
    Hatzakis, A
    TRANSFUSION, 1997, 37 (08) : 858 - 862
  • [7] Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference
    Sautto, Giuseppe
    Mancini, Nicasio
    Diotti, Roberta A.
    Solforosi, Laura
    Clementi, Massimo
    Burioni, Roberto
    ANTIVIRAL RESEARCH, 2012, 96 (01) : 82 - 89
  • [8] 2 HEPATITIS-C VIRUS GLYCOPROTEIN E2 PRODUCTS WITH DIFFERENT C-TERMINI
    MIZUSHIMA, H
    HIJIKATA, M
    ASABE, SI
    HIROTA, M
    KIMURA, K
    SHIMOTOHNO, K
    JOURNAL OF VIROLOGY, 1994, 68 (10) : 6215 - 6222
  • [9] Flexibility and intrinsic disorder are conserved features of hepatitis C virus E2 glycoprotein
    Stejskal, Lenka
    Lees, William D.
    Moss, David S.
    Palor, Machaela
    Bingham, Richard J.
    Shepherd, Adrian J.
    Grove, Joe
    PLOS COMPUTATIONAL BIOLOGY, 2020, 16 (02)
  • [10] Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein
    Hung, Ting-Chun
    Jassey, Alagie
    Liu, Ching-Hsuan
    Lin, Chien-Ju
    Lin, Chun-Ching
    Wong, Shu Hui
    Wang, Jonathan Y.
    Yen, Ming-Hong
    Lin, Liang-Tzung
    PHYTOMEDICINE, 2019, 53 : 62 - 69